VIDEO: Important role of measurable residual disease in ALL
Click Here to Manage Email Alerts
In this video, Lori Muffly, MD, MS, spoke with Healio about her presentation on the use of measurable residual disease in treating acute lymphoblastic leukemia from the Society of Hematologic Oncology Annual Meeting.
During the presentation, Muffly, associate professor of medicine in the division of blood and marrow transplantation and cellular therapy at Stanford University, focused on several questions in the field, including data supporting the use of ongoing monitoring in patients who achieve an MRD-negative remission early on.
“That’s an area where there’s a lot to be discovered and really kind of expanded upon in the research,” Muffly said.
Muffly also discussed the different technologies used for assessing MRD as well as their sensitivity and whether deeper MRD is important or relevant prognostically, noting that some data suggest it is beneficial in some settings whereas other data indicate it may be less helpful.
“This is an area where there is still exploration, but the main take home point is certainty that MRD using a validated tool with a sensitivity of at least 10-4 is standard of care if you’re managing patients with ALL,” Muffly said.
Collapse
Muffly L. Measurable residual disease in acute lymphoblastic leukemia. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 8-11, 2021 (virtual meeting).
Click Here to Manage Email Alerts